The epidermal growth factor receptor (EGFR) is among the most widely studied growth factor receptors due to its ubiquity and pleiotropic signaling effects.[1,2] EGFR is expressed by nearly all adult human tissues, with the notable exception of hematopoietic cells.[2,3] Activation of EGFR results in a range of effects, including cell proliferation, differentiation, migration, adhesion, and inhibition of apoptosis. It also enhances processes crucial to tumor growth and progression, such as angiogenesis, tumor invasiveness, and metastatic spread. EGFR is overexpressed by many human cancers, while its signaling is upregulated due to autocrine stimulation in others.[1,5] Its expression has been shown to correlate with disease progression, reduced survival, poor response to treatment, and chemotherapy resistance in several human cancers.
For these reasons, EGFR is a rational target for the design and development of novel agents that aim to distinguish malignant and nonmalignant cells. Two main categories of compounds have been developed: agents that target the extracellular domain of the receptor and those that target the intracellular tyrosine kinase (TK) domain (Table 1). Both approaches result in blockade of signal transduction, thereby preventing the downstream effects normally associated with EGFR activation.[4,5]
The monoclonal antibody cetuximab (Erbitux) is the first commercially available agent designed to target the EGFR extracellular domain; it is approved for use in patients with EGFR-expressing, metastatic colorectal cancer. Gefitinib (Iressa) and erlotinib (Tarceva) are small-molecule inhibitors of the TK domain, each initially approved for use in patients with advanced non-small-cell lung cancer who have progressed on at least one (erlotinib) or two (gefitinib) prior chemotherapy regimens.[7,8] (As of June 2005, the US Food and Drug Administration has limited the commercial use of gefitinib to those patients currently receiving and benefiting from the drug or those who have received it and benefited from it in the past, pending the outcomes of additional studies.)
Despite the differences in chemical structure and mechanism of action of these two drug classes, many of the resultant side effects are similar due to their effects on a common target. This article further describes the EGFR and adverse event profiles of the agents that target it, with the goal of distinguishing adverse events related to EGFR inhibition from those unique to the individual drugs.
The Epidermal Growth Factor Receptor
Structure and Activation
The EGFR, also known as HER1 or ErbB1, is a 170-kD glycoprotein that consists of an extracellular ligand-binding domain, a hydrophobic transmembrane region, and an intracellular TK domain. Ligands for the EGFR include EGF, transforming growth factor-alpha (TGF-α), amphiregulin, heparin-binding EGF, betacellulin, and epiregulin. EGFR exists as a monomer in the cell membrane. Upon ligand binding, individual receptors cluster on the cell surface, which facilitates dimerization. EGFR can form a homodimer with another EGFR monomer or a heterodimer with another member of the erbB family (eg, HER2/neu, HER3, or HER4).[4,11] Dimerization is followed by TK activation and autophosphorylation on tyrosine residues, key steps to the initiation of downstream physiologic and pathogenic events (Figure 1). Ultimately signaling is “turned off” by internalization of receptor/ligand complexes.[4,5,12]
The precise signaling pathways that are activated in response to EGFR-ligand binding depend on both the activating ligand and coreceptor to which EGFR dimerizes.[4,13] Major pathways include the MAPK and PI-3K/Akt pathways.[5,11] The Ras-Raf-MEK-MAPK pathway produces cell proliferation and angiogenesis, inhibits apoptosis, and increases metastatic spread. The PI-3K/Akt pathway affects cell survival, metabolism, and proliferation, and it inhibits apoptosis.
Physiologic Role of EGFR Signaling
Signaling by EGFR is critical for epithelial development, proliferation, and organogenesis. Studies with EGFR knockout mice demonstrate that the lack of EGFR results in embryonic and perinatal mortality. If born, these mice survive for only days to weeks, and they exhibit widespread physical abnormalities, including severe impairment of epithelial development in multiple organ systems such as the gastrointestinal tract, lungs, brain, skin, eyes, kidneys, and liver.[4,11,14] There are defects in hair development, respiratory distress, retarded growth, and progressive wasting in these animals. Conversely, activation of EGFR signaling via the administration of EGF enhanced the maturation of epithelial tissues in other murine studies, resulting in precocious eye opening and tooth eruption in newborn mice.
These findings suggest that EGFR signaling plays an important role in multiple organ systems. Expression of EGFR has been documented in tissues of the digestive tract, skin, eyes, thymus, and respiratory, urogenital, and endocrine systems (Table 2). No detectable levels of EGFR have been found in skeletal tissue, lymph nodes, spleen, or the central nervous or cardiovascular systems. Despite the ubiquity of EGFR, its role appears to be most important in the developing organism. The mitotic effects of exogenous EGF on mouse keratinocytes diminish with increasing age of the animal. The expression of EGFR on human skin cells also diminishes with age. In human fetal epidermis EGFR expression persists in all cell layers, whereas in adults there is limited distribution in normal skin. Indeed, in adults, EGFR expression is found primarily on epithelial cells with the highest proliferative potential—namely the basal keratinocytes—consistent with its role as a regulator of normal skin growth.[11,15,16]
Dr. Lenz has done consulting for and served on advisory boards and speakers bureaus for Bristol-Myers Squibb and Genentech. He has also served on advisory boards for ImClone.
1. Wells A: Molecules in focus: EGF receptor. Int J Biochem Cell Biol 31:637-643, 1999.
2. Bier H, Hoffman T, Haas I, et al: Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46:167-173, 1998.
3. Miettinen PJ, Berger JE, Meneses J, et al: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337-341, 1995.
4. Arteaga CL: The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19:32s-40s, 2001.
5. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(suppl 4):2-8, 2002.
6. Erbitux (Cetuximab) package insert. ImClone Systems, NY, and Bristol-Myers Squibb, Princeton, NJ; August 2005.
7. Iressa (gefitinib) tablets [package insert]. AstraZeneca Pharmaceuticals, Wilmington, DE; November 2004.
8. Tarceva (erlotinib) tablets [package insert]. Genentech, South San Francisco, CA, and OSI Pharmaceuticals, Melville, NY; 2004.
9. Food and Drug Administration: FDA public health advisory: New labeling and distribution program for gefitinib (Iressa). Available at http://www.fda.gov/cder/drug/infopage/gefitinib/default.htm. Accessed February 28, 2006.
10. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995.
11. Yano S, Kondo K, Yamaguchi M, et al: Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23:3639-3650, 2003.
12. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 94:1593-1611, 2002.
13. Moghal N, Sternberg PW: Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 11:190-196, 1999.
14. Threadgill DW, Dlugosz AA, Hansen LA, et al: Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269:230-234, 1995.
15. Nanney LB, Stoscheck CM, King LE, et al: Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 94:742-748, 1990.
16. Bunn PA, Franklin W: Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 29(suppl 14):38-44, 2002.
17. Mendelsohn J: Blockade of receptors for growth factors: An anticancer therapy. The Fourth Annual Joseph H. Burchenal American Association for Cancer Research clinical research award lecture. Clin Cancer Res 6:747-753, 2000.
18. Grandis JR, Melhem MF, Barnes EL, et al: Quantitative immunohistochemical analysis of transforming growth factor-a and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78:1284-1292, 1996.
19. Saltz LB, Meropol NJ, Loehrer PJ, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004.
20. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001.
21. Herbst RS, Maddox AM, Rothenberg M, et al: Selective oral epidermal growth factor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002.
22. Schrag D, Chung KY, Flombaum C, et al: Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005 97:1221-1224.
23. Food and Drug Administration. 2005 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. Available at http://www.fda.gov/medwatch/safety/2005/safety05.htm#Erbitux. Last accessed February 9, 2006.
24. Perez-Soler R, Delord JP, Halpern A, et al: HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10:345-356, 2005.
25. Perez-Soler R: Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 17(suppl):23-28, 2003.
26. Needle MN: Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 29(suppl 14):55-60, 2002.
27. Bouche O, Brixi-Benmansour H, Bertin A, et al: Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 16:1711-1172, 2005.
28. Boucher KW, Davidson K, Mirakhur B, et al: Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 45:632-633, 2002.
29. Dueland S, Sauer T, Lund-Johansen F, et al: Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 42:345-346, 2003.
30. Herbst RS, LoRusso PM, Purdom M, et al: Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clin Lung Cancer 4:366-369, 2003.
31. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002.
32. Kimyai-Asadi A, Jih MH: Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors [letter]. Arch Dermatol 138:129-130, 2002.
33. Sibilia M, Wagner EF: Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269:234-238, 1995.
34. Murillas R, Larcher F, Conti CJ, et al: Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 14:5216-5223, 1995.
35. Clark GM, Perez-Soler R, Siu L, et al: Rash severity is predictive of increased survival with erlotinib HCl (abstract 786). Proc Am Soc Clin Oncol 22:196, 2003.
36. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 16:3238-3247, 2004.
37. Saltz L, Kies M, Abbruzzese JL, et al: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies (abstract 817). Proc Am Soc Clin Oncol 22:204, 2003.
38. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004.
39. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003.
40. Janne PA, Gurubhagavatula S, Yeap BY, et al: Outcomes of patients with advanced non-small-cell lung cancer treated with gefitinib (ZD1839, Iressa) on an expanded access study. Lung Cancer 44:221-230, 2004.
41. Cohen EEW, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003.
42. West HL, Franklin WA, Gumerlock PH, et al: Gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126 (abstract 7014) [and slide presentation]. Proc Am Soc Clin Oncol 22:14S, 2004.
43. Rich JN, Reardon DA, Peery T, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142, 2004.
44. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425-1433, 2005.
45. Seto T, Yamamoto N: Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey (abstract 7064) [and slide presentation]. Proc Am Soc Clin Oncol 23:629, 2004.
46. Shah NT, Kris MG, Pao W, et al: Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23:165-174, 2005.
47. Hotta K, Harita S, Bessho A, et al: Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group (abstract 7063). Proc Am Soc Clin Oncol 23:629, 2004.
48. Nakagawa M, Teramukai S, Tada H, et al: Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study (abstract 7190). J Clin Oncol 23(suppl 16S):667s, 2005.
49. Tamura K, Okamoto I, Kurata T, et al: Low expressions of surfactant-associated protein (SP-A) in cancer tissues or in normal bronchial epithelial cells by immuno-histochemistry predict interstitial lung diseases (ILDs) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC) (abstract 7188) [and slide presentation]. J Clin Oncol 23(suppl 16S):667s, 2005.
50. Cheifetz A, Mayer L: Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 72:250-256, 2005.
51. Cheng JD, Adams GP, Robinson MK, et al: Monoclonal antibodies, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, pp 445-456, 7th ed. Philadelphia, Lippincott Williams & Wilkins, 2005.
52. Dillman RO: Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18:465-471, 1999.
53. Khazaeli MB, LoBuglio AF, Falcey JW, et al: Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumors (abstract 808). Proc Am Soc Clin Oncol 19:207a, 2000.
54. Phipatanakul W, Eggleston PA, Wright EC, et al: Mouse allergen. II. The relationship of mouse allergen exposure to mouse sensitization and asthma morbidity in inner-city children with asthma. J Allergy Clin Immunol 106:1075-1080, 2000.
55. Rowinsky EK, Schwartz GH, Gollob JA, et al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015, 2004.
56. Weiner LM, Belldegrun A, Rowinsky E, et al: Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies (abstract 3059). J Clin Oncol 23(suppl 16S):206s, 2005.
57. Hecht JR, Patnaik A, Malik I, et al: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis (abstract 3511). Proc Am Soc Clin Oncol 23:248, 2004.
58. Crawford J, Sandler AB, Hammond LA, et al: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) (abstract 7083). Proc Am Soc Clin Oncol 23:634, 2004.
59. Vanhoefer U, Tewes M, Rojo F, et al: Phase I study of the humanized anti-
epidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22:175-184, 2004.